European Group for Blood & Marrow Transplantation Allograft Risk Score

Risk assessment before allogeneic stem cell transplantation

1. Sum the scores for each risk factor

Risk factor0 points1 point2 points
Age (y)< 2020 - 40> 40
Disease stage*EarlyInter­mediateLate
Time between diagnosis and transplant (m)< 12> 12-
Donor typeHLA ident­ical siblingUnrelated-
Donor / recipient sexAny other comb­inationFemale donor, male reci­pient

2. Use total score to estimate 5 year overall survival and treatment-related mortality

Myeloablative transplantation
Score5 year OSTRM
070%16%
162%23%
254%29%
343%34%
433%41%
524%47%
≥ 623%52%
Non-myeloablative transplantation
Score5 year OSTRM
081%15%
169%16%
252%23%
344%27%
435%29%
532%33%
≥ 623%37%

This European Group for Blood and Marrow Transplantation (EBMT) Risk Score was originally developed for transplants performed for chronic myeloid leukemia (CML) alone, but was subsequently validated in 56505 children and adults who underwent allogeneic stem cell transplantation between 1980 and 2005 for a range of hematological malignancies.1

Transplants were performed at 384 centres in 47 countries. Syngeneic twin donor and nonidentical family donor transplants were excluded from the analysis. Diseases for which fewer than 1000 patients were transplanted were also excluded from analysis.

EBMT: European Group for Blood & Marrow Transplantation
m: months
OS: overall survival
TRM: treatment-related mortality
y: years